신풍
신풍제약 Stock: price and insider trades · South Korea
신풍제약: what insiders have been doing
신풍제약 has a thin disclosure history in our data (latest filing: 2 July 2021). New filings will appear here as soon as they are published. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.
Insider Decl.
7
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Fundamental score
Ranked 17,821 of 26,911 companies
41.0
score / 100
Value37
Quality45
FCF yld2.6%
Earn yld1.7%
EV/EBITDA25.0x
ROE-0.3%
Gross mgn44%
Net mgn3.8%
Debt/EBITDA2.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
₩9,470
Analyst consensus
Income statement
Revenue₩234.7B
Gross profit₩102.7B44% margin
EBITDA₩22.5B10% margin
Net income₩8.8B-0.3% margin
Valuation
Beta1.14
Balance sheet & cash
Market cap₩508.5B
Total debt₩55.9B
Free Cash Flow₩13.3B
Debt / Equity19%
Profitability & ownership
ROE-0.3%
ROA0.5%
% insiders32.0%
% institutions2.6%
Last declaration on 2 July 2021
Declarations7 total
- ●Executives0DART
- ●Executives0DART
- ●Executives0DART
- ●Executives0DART
- ●Executives0DART
- ●Executives0DART
- ●Executives0DART
7 of 7 declarations
About 신풍제약
신풍제약 is a South Korean pharmaceutical company listed on the KRX. It specializes in the development and commercialization of innovative drugs.
